$1.1 B

EPIX Mkt cap, 17-Jun-2021
ESSA Pharma Net income (Q1, 2021)-6.5 M
ESSA Pharma Cash, 31-Dec-202052.5 M
ESSA Pharma EV1 B

ESSA Pharma Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

4.9m6.7m12.1m

General and administrative expense

5.9m5.5m11.4m

Operating expense total

11.7m12.8m24.1m

Interest income

42.7k26.3k559.7k

Pre tax profit

(11.6m)(10.4m)(23.7m)

Income tax expense

27.0k37.9k(288.6k)

Net Income

(11.6m)(10.4m)(23.4m)

EPS

(2.5)(1.2)(1.0)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

R&D expense

1.3m1.5m2.0m2.6m4.6m2.7m4.5m

General and administrative expense

1.2m1.8m1.2m2.1m4.9m2.2m2.2m

Operating expense total

2.7m3.4m3.3m4.9m9.6m5.1m6.7m

Interest income

101.0k205.6k172.3k35.7k

Pre tax profit

(2.7m)(3.4m)(3.3m)(4.9m)(9.4m)(4.9m)(6.6m)

Income tax expense

9.7k12.3k16.0k(278.0k)4.0k(35.1k)

Net Income

(2.7m)(3.4m)(3.3m)(4.6m)(9.4m)(4.9m)(6.5m)

EPS

(0.4)(0.5)(0.5)(0.2)(0.4)(0.2)(0.2)

ESSA Pharma Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

14.8m53.3m56.3m

Accounts Receivable

297.3k360.8k309.5k

Prepaid Expenses

470.2k615.5k1.6m

Current Assets

15.6m54.3m80.3m

Total Assets

16.0m54.8m80.6m

Accounts Payable

678.6k

Short-term debt

2.8m3.7m59.1k

Current Liabilities

3.3m5.6m1.2m

Long-term debt

3.5m

Total Debt

6.3m3.7m59.1k

Total Liabilities

6.9m5.6m1.3m

Common Stock

40.2m76.2m131.1m

Additional Paid-in Capital

31.2m

Retained Earnings

(44.4m)(54.8m)(81.0m)

Total Equity

9.2m49.2m79.2m

Debt to Equity Ratio

0.7 x0.1 x0 x

Debt to Assets Ratio

0.4 x0.1 x0 x

Financial Leverage

1.8 x1.1 x1 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

12.2m8.6m4.9m45.9m39.9m36.5m52.5m

Accounts Receivable

247.6k274.9k350.1k349.5k348.6k231.2k

Prepaid Expenses

377.2k172.8k471.8k955.9k913.0k1.1m

Current Assets

12.8m5.3m46.8m41.2m37.7m75.9m

Total Assets

13.2m9.6m7.1m47.4m41.8m38.3m76.2m

Accounts Payable

1.4m

Short-term debt

2.9m3.0m113.9k114.7k87.3k30.0k

Current Liabilities

3.6m3.7m5.0m1.2m1.5m1.3m2.0m

Long-term debt

2.8m2.2m1.4m26.6k

Total Debt

5.7m2.2m4.4m140.5k114.7k87.3k30.0k

Total Liabilities

6.4m5.9m6.5m1.3m1.5m1.4m2.1m

Common Stock

42.3m49.0m76.2m76.6m76.8m134.4m

Additional Paid-in Capital

29.3m

Retained Earnings

(47.1m)(53.8m)(59.4m)(68.8m)(73.7m)(87.5m)

Total Equity

6.8m3.7m618.8k46.0m40.3m36.9m74.1m

Debt to Equity Ratio

0.8 x0.6 x7.1 x0 x0 x0 x0 x

Debt to Assets Ratio

0.4 x0.2 x0.6 x0 x0 x0 x0 x

Financial Leverage

1.9 x2.6 x11.4 x1 x1 x1 x1 x

ESSA Pharma Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(11.6m)(10.4m)(23.4m)

Depreciation and Amortization

34.5k18.3k110.3k

Accounts Receivable

(35.9k)(59.7k)89.9k

Accounts Payable

(1.1m)(1.0m)(46.4k)

Cash From Operating Activities

(10.2m)(12.2m)(17.0m)

Cash From Investing Activities

(201.4k)(45.5k)(21.7m)

Long-term Borrowings

(2.0m)(2.8m)(4.0m)

Cash From Financing Activities

21.3m50.8m41.8m

Net Change in Cash

10.9m38.5m3.0m

Interest Paid

563.3k401.9k32.2k

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.7m)(6.1m)(9.4m)(4.6m)(14.0m)(18.9m)(6.5m)

Depreciation and Amortization

4.6k9.1k13.7k32.2k64.3k96.5k27.6k

Accounts Receivable

53.0k56.6k25.6k10.1k12.5k13.0k102.3k

Accounts Payable

213.8k252.3k617.0k(163.0k)92.1k(83.2k)867.8k

Cash From Operating Activities

(1.9m)(4.6m)(7.1m)(3.4m)(9.3m)(12.6m)(3.9m)

Cash From Investing Activities

201.4k

Long-term Borrowings

(683.2k)(1.4m)(2.1m)(3.2m)(3.3m)(3.3m)(30.3k)

Cash From Financing Activities

(802.7k)(1.6m)(3.0m)(4.0m)(4.1m)(4.3m)150.9k

Net Change in Cash

(2.7m)(6.2m)(10.0m)(7.4m)(13.4m)(16.8m)(3.8m)

Interest Paid

119.5k227.2k322.7k720.2k720.2k720.2k

ESSA Pharma Ratios

USDFY, 2018

Debt/Equity

0.7 x

Debt/Assets

0.4 x

Financial Leverage

1.8 x